- Policy
- “Neglecting cost-effectiveness is dereliction of duty"
- by Kim, Jung-Ju May 19, 2020 06:07am
- Answering to the criticism that National Health Insurance (NHI) coverage enhancement initiative is toughening the barrier of pharmaceutical reimbursement listing and standard, Korean health authority officials urged the cost-effectiveness should be further reinforced. Recently appointed Director Yang Yoon Seok of the Pharmaceutical Benefit
- Policy
- Reimbursement on Ibrance-Faslodex available from June
- by Lee, Hye-Kyung May 19, 2020 06:07am
- From June 1, the healthcare reimbursement would be granted on the combined use of Pfizer Pharmaceutical Korea’s HER2-negative breast cancer treatment Ibrance (palbociclib) capsule and Faslodex (fulvestrant). National Health Insurance Service (NHIS) has settled on a negotiation over an indication expansion of the already listed drug and lis
- Company
- Bispecific antibody by Yuhan & ABL BIO debuts at the AACR 20
- by An, Kyung-Jin May 19, 2020 06:06am
- YH32367/ABL-105, which Yuhan & ABL Bio are jointly developing, debuts on the international stage. Yuhan announced on the 15th that it will announce the results of the preclinical efficacy test of the bispecific antibodies for cancer immunotherapy 'YH32367 (ABL-105)' at the American Association of Cancer Research's 2nd online academic confere
- Company
- Will Hanmi also target Stivarga's patent?
- by Kim, Jin-Gu May 19, 2020 06:06am
- Hanmi's generic launch of Nexavar (Sorafenib) is imminent. Hanmi is considering internally reviewing a plan to target the patent of 'Stivarga (Legorafenib)', a secondary target treatment for liver cancer. If Hanmi succeeds in overcoming patents to Nexavar and Stivarga, it is expected that a lineup of targeted treatments for liver cancer will
- Company
- Pfizer launches Vyndaqel followed by Vyndamax in Korea
- by Eo, Yun-Ho May 18, 2020 06:16am
- Pfizer is expecting to introduce 'Vyndamax' following 'Vyndaqel'. According to the related industry, Pfizer is in the process of approving for Vyndamax (Tafamidis meglumine) by the MFDS, a treatment for cardiomyopathy caused by hereditary transthyretin amyloid polyneuropathy (hATTR-PN) and transthyretin mediated amyloidosis (ATTR-CM). It
- Opinion
- [Reporter’s View] COVID-19 and vaccine self-sufficiency
- by An, Kyung-Jin May 18, 2020 06:15am
- The U.S. and Europe have sparked a conflict over COVID-19 vaccine still in development. The tension arose when a multinational pharmaceutical company Sanofi announced its intention to prioritize the distribution of the vaccine to the U.S., in case the company successfully completes the development. During an interview with Bloomberg, San
- Policy
- The mechanism by SGLT2 inhibitors was first identified
- by Lee, Hye-Kyung May 18, 2020 06:15am
- Research has shown that the 'diabetes treatment agent' SGLT2 inhibitor lowers the risk of cardiovascular disease by inhibiting inflammatory cytokine secretion. Jung-Sun Kim, Professor of cardiology, Yong-ho Lee Professor of endocrinology, and Sang-Guk Lee Professor of laboratory medicine at Severance Hospital and So Ra Kim, Professor of hosp
- Policy
- Patients suffer from quarrels between companies & the HIRA
- by Lee, Jeong-Hwan May 18, 2020 06:15am
- Patients urged Ono Pharma Korea, BMS Korea, and MSD Korea to come up with a reasonable burden-sharing plan that the health authorities could accept. Patients have been urging to expand the health benefits of Opdivo (Nivolumab) and Keytruda (Pembrolizumab), which have various therapeutic indications, such as lung cancer and kidney cancer.
- Company
- Hanmi on legal action against Sanofi returning efpeglenatide
- by Chon, Seung-Hyun May 18, 2020 06:14am
- A multinational pharmaceutical company Sanofi has decided to return the rights on antidiabetic candidate medicine efpeglenatide back to Hanmi Pharmaceutical. Apparently, the French-based company is putting an abrupt brake on the development of efpeglenatide, licensed out as the biggest Korean-developed pipeline in 2015. Hanmi Pharmaceutical expl
- Policy
- Xeljanz was rejected for the uninsured benefit
- by Lee, Hye-Kyung May 18, 2020 06:14am
- The application to use 'Xeljanz (Tofacitinib citrate)' from Pfizer Korea, which has been approved for rheumatoid arthritis and ulcerative colitis, was rejected for the uninsured benefit for patients with dermatomyositis or severe alopecia. The HIRA is applying in advance for the uninsured benefit that is not approved by the MFDS in orde
